M Jager


Affiliation: Heinrich Heine University
Country: Germany


  1. Jager M, Thorey F, Westhoff B, Wild A, Krauspe R. In vitro osteogenic differentiation is affected in Wiedemann-Rautenstrauch-Syndrome (WRS). In Vivo. 2005;19:831-6 pubmed
    ..Our data suggest a lack of cellular differentiation capacity in WRS patients, which may be responsible for the clinical appearance and symptoms of this rare disorder. ..
  2. Jager M, Sager M, Knipper A, Degistirici O, Fischer J, Kogler G, et al. [In vivo and in vitro bone regeneration from cord blood derived mesenchymal stem cells]. Orthopade. 2004;33:1361-72 pubmed
    ..Human USSC are a mesenchymal multipotent stem cell population that shows osteoblastic differentiation onto a collagen I/III carrier in vitro as well as in an athymic rat in vivo. ..
  3. Jager M, Degistirici O, Knipper A, Fischer J, Sager M, Krauspe R. Bone healing and migration of cord blood-derived stem cells into a critical size femoral defect after xenotransplantation. J Bone Miner Res. 2007;22:1224-33 pubmed
    ..Human cord blood-derived stem cells showed significant engraftment in bone marrow, survived within a collagen-TCP scaffold up to 4 wk, and increased local bone formation in a nude rat's femoral defect. ..
  4. Jager M, Krauspe R. Antigen expression of cord blood derived stem cells under osteogenic stimulation in vitro. Cell Biol Int. 2007;31:950-7 pubmed
    ..Future investigations should show the role of cytomechanical forces in the differentiation of cord blood derived progenitor cells and also if a cell-loaded collagen I/III scaffold is appropriate to stimulate bone regeneration in vivo. ..
  5. Jager M, Hernigou P, Zilkens C, Herten M, Fischer J, Krauspe R. [Cell therapy in bone-healing disorders]. Orthopade. 2010;39:449-62; quiz 463 pubmed publisher
    ..Most clinical trials report successful bone regeneration after the application of mixed cell populations from bone marrow. ..
  6. Jager M, Herten M, Fochtmann U, Fischer J, Hernigou P, Zilkens C, et al. Bridging the gap: bone marrow aspiration concentrate reduces autologous bone grafting in osseous defects. J Orthop Res. 2011;29:173-80 pubmed publisher
    ..BMAC combined with HA can reduce the time needed for healing of bone defects when compared to BMAC in combination with collagen sponge. ..
  7. Jager M, Westhoff B, Wild A, Krauspe R. [Computer-assisted periacetabular triple osteotomy for treatment of dysplasia of the hip]. Z Orthop Ihre Grenzgeb. 2004;142:51-9 pubmed
  8. Jager M, Fischer J, Dohrn W, Li X, Ayers D, Czibere A, et al. Dexamethasone modulates BMP-2 effects on mesenchymal stem cells in vitro. J Orthop Res. 2008;26:1440-8 pubmed publisher
    ..In conclusion, BMP-2 enhances DAG-induced osteogenic differentiation in mesenchymal bone marrow cells. Both agents interact in various ways and can modify osteoblastic bone formation. ..
  9. Jager M, Begg M, Ready J, Bittersohl B, Millis M, Krauspe R, et al. Primary total hip replacement in childhood, adolescence and young patients: quality and outcome of clinical studies. Technol Health Care. 2008;16:195-214 pubmed
    ..Sufficient data about the ISR of stem and/or sockets were available in 50 papers. Most published studies analyzed inhomogeneous study populations; study variables vary as do the implants used for treatment. ..

More Information


  1. Jager M, Zilkens C, Westhoff B, Jelinek E, Kozina G, Krauspe R. Efficiency of iloprost treatment for chemotherapy-associated osteonecrosis after childhood cancer. Anticancer Res. 2009;29:3433-40 pubmed
    ..Our current data confirm the findings of other investigators that healing of advanced stages of AVN is not possible, but that in early stages of AVN, pain relief and an improvement of joint function can be achieved by iloprost. ..
  2. Jager M, Tillmann F, Thornhill T, Mahmoudi M, Blondin D, Hetzel G, et al. Rationale for prostaglandin I2 in bone marrow oedema--from theory to application. Arthritis Res Ther. 2008;10:R120 pubmed publisher
    ..We found a significant decrease in BME on MRI scans after iloprost application. In addition to other drugs, iloprost may be an alternative substance which should be considered in the treatment of BME/AVN-associated pain. ..
  3. Jager M, Schultheis A, Westhoff B, Krauspe R. Osteogenic progenitor cell potency after high-dose chemotherapy (COSS-96). Anticancer Res. 2005;25:947-54 pubmed
    ..The uniform treatment concept of a high-dose polychemotherapy pre- and postoperatively improved the survival rate of these patients significantly. One severe side-effect of COSS chemotherapy is multiple osteonecrosis...
  4. Jager M, Westhoff B, Portier S, Leube B, Hardt K, Royer Pokora B, et al. Clinical outcome and genotype in patients with hereditary multiple exostoses. J Orthop Res. 2007;25:1541-51 pubmed
    ..c) 2007 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 25:1541-1551, 2007...
  5. Jager M, Westhoff B, Zilkens C, Weimann Stahlschmidt K, Krauspe R. [Indications and results of corrective pelvic osteotomies in developmental dysplasia of the hip]. Orthopade. 2008;37:556-70, 572-4, 576 pubmed publisher
    ..The aim of these procedures is to prevent early secondary osteoarthritis. For patients and families as well as for the orthopaedist, risk-benefit analysis is of major interest...
  6. Jager M, Jelinek E, Wess K, Scharfstädt A, Jacobson M, Kevy S, et al. Bone marrow concentrate: a novel strategy for bone defect treatment. Curr Stem Cell Res Ther. 2009;4:34-43 pubmed
    ..Although strong efforts have been made over the last decade to introduce stem cell and tissue engineering treatment strategies to the field of orthopaedics, only few clinical applications are currently available...